0.20
0.04 (25.0%)
0.04 (25.0%)
Upgrade to Real-Time
Market Closed
Best deals to access real time data! |
|
Small Cap Basic
Monthly Subscription
for only
|
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
DDE w/Realtime (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Neuropathix Inc (QB) | NPTX | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.04 | 25.0% | 0.20 | 15:18:38 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.16 | 0.142 | 0.20 | 0.20 | 0.16 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 0.195 | 0.21 | 0.015 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 28 | 74,955 | $ 0.173028 | $ 12,969 | - | 0.13 - 0.805 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:17:18 | 6,500 | $ 0.20 | USD |
Neuropathix (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 15.05M | 75.25M | 10.92M | $ - | $ - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 7.60k | $ - | 0.00% | - | - |
Neuropathix (QB) News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NPTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.18 | 0.20 | 0.13 | 0.1556588 | 114,232 | 0.02 | 11.11% |
| 1 Month | 0.24 | 0.24 | 0.13 | 0.1674913 | 60,075 | -0.04 | -16.67% |
| 3 Months | 0.33 | 0.805 | 0.13 | 0.219166 | 40,610 | -0.13 | -39.39% |
| 6 Months | 0.33 | 0.805 | 0.13 | 0.219166 | 40,610 | -0.13 | -39.39% |
| 1 Year | 0.33 | 0.805 | 0.13 | 0.219166 | 40,610 | -0.13 | -39.39% |
| 3 Years | 0.33 | 0.805 | 0.13 | 0.219166 | 40,610 | -0.13 | -39.39% |
| 5 Years | 0.33 | 0.805 | 0.13 | 0.219166 | 40,610 | -0.13 | -39.39% |
Neuropathix (QB) Description
| Neuropathix, Inc., formerly Kannalife, Inc. ("Neuropathix"), is a socially responsible pain management life sciences company. For the past ten years, Neuropathix has discovered, developed and patented a global intellectual property estate of novel new therapeutic agents designed to prevent and reverse neuropathic pain, reduce oxidative stress, and act as anti-inflammatory neuroprotectants. Neuropathix was the only company to hold an exclusive license with National Institutes of Health - Office of Technology Transfer ("NIH-OTT") for the Commercialization of U.S. Patent #6630507, "Cannabinoids as Antioxidants and Neuroprotectants" (the "'507 Patent"). This early and extensive pre-clinical research on cannabidiol (CBD) led Neuropathix to develop its own patented molecules lead by KLS-13019 called by Sports Illustrated as a "super-CBD" and currently covered under global patents awarded including U.S. Patent #9611213, "Functionalized 1,3-benzene diols and their method of use for the treatment of hepatic encephalopathy". Neuropathix continues to conduct its research and development efforts at the Bucks County Pennsylvania Biotechnology Center in Doylestown, PA, for a target drug candidate to treat Hepatic Encephalopathy ("HE"), Chronic Traumatic Encephalopathy ("CTE") and Chemotherapy Induced Peripheral Neuropathy ("CIPN"). |
